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AbsTrACT
background Recombinant factor VIIa (rFVIIa) has been 
used off-label as an adjunct in the reversal of warfarin 
therapy and management of hemorrhage after trauma. 
Only a handful of these reports are rigorous studies, from 
which results regarding safety and effectiveness have 
been mixed. There remains no clear consensus as to the 
role of rFVIIa in traumatic brain injury (TBI).
Methods Eleven level 1 trauma centers provided 
clinical data and head CT scans of patients with 
a Glasgow Coma Scale (GCS) score of ≤13 and 
radiographic evidence of TBI. A propensity score (PS) to 
receive rFVIIa in those surviving ≥2 days was calculated 
for each patient based on patient demographics, 
comorbidities, physiology, Injury Severity Score, admission 
GCS score, and treatment center. Patients receiving rFVIIa 
within 24 hours of admission were matched to patients 
who did not receive rFVIIa for outcomes assessment. 
Subgroup analysis evaluated patients with primary head 
injury with PS matching.
results There were 4284 patient observations; 
129 received rFVIIa. Groups were comparable after 
matching. No differences in mortality or morbidity were 
found. Improvement in GCS score from admission to 
discharge was less among those receiving rFVIIa (5.5 vs. 
2.4; P value 0.001); however, there was no difference 
in average GCS score at discharge. No significant 
differences in outcomes were identified in patients with 
isolated TBI receiving rFVIIa.
Discussion rFVIIa in early management of TBI is 
not associated with a decreased risk of mortality or 
morbidity, and may negatively impact recovery and 
functional status at discharge in the severely injured 
patient with polytrauma.
Level of evidence Level III.
study type Therapeutic/care management.
bACkgrounD
Traumatic brain injury (TBI) and hemorrhage are 
the first and second most common causes of death, 
respectively, in the setting of trauma.1 Despite injury 
prevention efforts, TBI-related emergency room 
visits have increased over the past decade, with falls 
accounting for 40% of all TBIs.2 Although advances 
in supportive care have contributed to decreased 
TBI mortality, fall-related deaths are on the rise, 
with the majority occurring among patients aged 65 
years and over.3-5 
The pathophysiology of polytrauma is such 
that post-traumatic stressors and complications 
(eg, infections, reperfusion injury, operative inter-
ventions, and so on) induce a second insult that 
further augments the initial inflammatory response, 
increasing the risk of multiple organ dysfunction 
syndrome (MODS). Likewise, severe TBI has been 
associated with increased activation of various 
inflammatory mediators, which in turn leads to 
consumption of existing coagulation factors and 
activation of anticoagulation pathways.6 In the 
setting of polytrauma, this resulting TBI coagulop-
athy can contribute to ongoing acute hemorrhage 
both within the brain and at other sites, thereby 
increasing blood product requirements necessary 
for adequate resuscitation.
Recombinant factor VIIa (rFVIIa) in the setting 
of trauma is an attractive treatment option given 
that replacement of depleted endogenous factor 
VII (FVII) may slow bleeding in the setting of TBI 
coagulopathy. Among the general trauma popula-
tion, rFVIIa was not associated with improvement 
in survival, but had a small positive effect on trans-
fusion requirements and rates of adult respiratory 
distress syndrome (ARDS).7 8 As such, support for 
the continued use of rFVIIa in the trauma setting 
stems from studies showing its efficacy in patients 
on anticoagulation. Although rFVIIa can effectively 
and rapidly normalize traditional (eg, international 
normalized ratio (INR), partial prothromboplastin 
time (PTT) and emerging (eg, thromboelastography 
(TEG)) parameters used to characterize the coagu-
lopathic state for patients on anticoagulants, some 
studies have failed to show a clinical benefit.9-11 
Data supporting rFVIIa use in the setting of TBI are 
less convincing and limited by the marginal quality 
of available prospective reports.11-13 Although there 
are several studies evaluating the evolution of intra-
cranial hemorrhage (ICH) after rFVIIa adminis-
tration, there has been no formal evaluation of 
functional outcomes of patients with TBI receiving 
rFVIIa.9 10 14
The known characteristics of rFVIIa—the rapid 
correction of coagulation parameters, low infusion 
volume, and reasonable safety profile—make it 
an attractive hemostatic adjunct for correction of 
coagulopathy particularly in patients with TBI with 
limited physiologic ability to tolerate large volume 
resuscitations. We therefore sought to determine if 
its use in a large group of patients with TBI was 
associated with improved outcomes through a 
propensity score analysis.
MeThoDs
Data acquisition
Retrospective data of patients with TBI were 
acquired from 11 level 1 US trauma centers from 
2008 to 2009, as described previously.15 Inclusion 
criteria included age 16 years or older, evidence of 
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blunt TBI on admission head CT, and admission Glasgow Coma 
Scale (GCS) score of 13 or less. Patient demographics (age, 
gender, smoking), coagulation status (±warfarin), pre-existing 
comorbidities, and actual admission CT scans were collected 
using an online web-portal data entry system developed in 
conjunction with the American Association for the Surgery of 
Trauma and Acute Care Surgery. CT scans were reviewed by the 
primary research site and graded according to the Marshall clas-
sification scheme.16 Comorbidities were considered both indi-
vidually and as a composite dichotomous variable representing 
the presence of any known pre-existing medical condition at the 
time of admission (table 1). Trauma mechanism (blunt vs. pene-
trating), admission physiology, labs, degree of coagulopathy, and 
initial resuscitation requirements were also collected.
outcomes
The primary outcome of interest was inhospital mortality. 
Deaths occurring within the first 24 hours of admission were 
excluded from all further analyses. The secondary outcomes 
consisted of morbidities commonly occurring among patients 
with trauma admitted to intensive care units (ICUs) and with 
prolonged hospitalizations (ventilator-associated pneumonia, 
ARDS, deep venous thrombosis (DVT), catheter-related blood 
stream infection, abscess, or meningitis), as well as functional 
status at discharge (GCS score at discharge, discharge disposi-
tion). Discharge disposition was treated as a dichotomous vari-
able, with surviving patients being discharged to either a private 
residence versus a rehabilitation facility, a long-term assisted 
care, or skilled nursing facility. These categories for disposition 
were thought to reflect differing levels of functionality given the 
amount and type of care required.
Propensity score matching
To overcome the inherent differences noted between the popula-
tion receiving rFVIIa in the setting of TBI and those not, patients 
from the rFVIIa group were matched 1:2 with a similar patient 
not receiving rFVIIa (control). Patients were matched using the 
caliper (0.05) nearest neighbor matching method without replace-
ment. Matching was based on the following demographic and 
admission variables: age, sex, body mass index, history of stroke 
or liver disease, trauma mechanism, admission vitals, number of 
units of packed red blood cells (RBC) and fresh frozen plasma 
transfused during the initial 24 hours, Marshall score, admission 
GCS score, paralytic at time of GCS, Injury Severity Score (ISS), 
presence of inhouse neurosurgery attending, and admitting 
hospital. Matching produced 145 patients (96 controls, 49 treat-
ment) that included all measure of injuries that were balanced 
across all variables. A subpopulation analysis of patients with 
primarily head injury was matched on the same variables, but 
with head Abbreviated Injury Scale (AIS) scores used in place 
of ISS. In this population, all patients with non-head AIS scores 
greater than 2 were excluded from matching to create a predom-
inantly isolated head injury population. Matching within this 
subpopulation identified 57 patients (37 controls, 20 treatment) 
and balanced across all variables except time from injury to 
arrival (table 2).
statistical analysis
Demographic and variables gathered on arrival in the trauma 
bay were compared using Pearson’s χ2 test for categorical vari-
ables, two-sample t-test for continuous or interval variables, and 
Kruskal-Wallis for ordinal variables. Comparison of prematching 
and postmatching outcome measures for rFVIIa and no rFVIIa 
groups was performed using Mantel-Haenszel OR for cate-
gorical variables, Student’s t-test for continuous variables, and 
Wilcoxon rank-sum for ordinal variables. All statistical analyses 
were performed using Stata V.11.0. A P value of less than 0.05 
was considered to be statistically significant.
resuLTs
Population characteristics
The complete data set included 4284 trauma activations, of 
which 501 were censored for death within 24 hours of admis-
sion. Among those succumbing to injury within 24 hours, 
34 (6.8%) received rFVIIa as compared with 2.7% of initial 
survivors. In total 129 patients with trauma received rFVIIa, 
of whom 26.4% died shortly after admission and were 
Table 1 Cohort demographics, prematching and postmatching
Prematching Postmatching, all comers Postmatching, primary TbI
−FVII
(n=3366)
+FVII
(n=95) P value
−FVII
(n=96)
+FVII
(n=49) P value
−FVII
(n=37)
+FVII
(n=20) P value
Age 41 (21) 49 (23) <0.001 52 (23) 50 (22) 0.570 57 (23) 59 (21) 0.675
Male 75.4% 61.0% 0.001 56.3% 57.1% 0.918 56.8% 60.0% 0.813
BMI 25.9 (6.3) 26.7 (6.4) 0.269 25.7 (6.8) 26.9 (5.9) 0.291 26.7 (7.8) 27.2 (6.5) 0.813
Smoker 7.4% 2.1% 0.049 6.3% 0% 0.074 5.4% 0% 0.290
Warfarin 2.0% 17.9% <0.001 9.4% 14.3% 0.372 13.5% 25.0% 0.277
Comorbidity 12.5% 23.2% 0.002 26.0% 30.6% 0.560 35.1% 35.0% 0.992
  Previous MI 1.7% 4.2% 0.071 4.2% 4.1% 0.981 2.7% 0% 0.458
  Prior stroke 1.8% 5.3% 0.014 9.4% 6.1% 0.501 5.4% 10.0% 0.517
  CHF 1.1% 2.1% 0.339 4.2% 2.0% 0.507 2.7% 0% 0.458
  COPD 1.2% 1.1% 0.904   0%   0% 1.000 5.4% 0% 0.290
  Diabetes 6.6% 9.5% 0.268 4.2% 10.2% 0.154 13.5% 20.0% 0.522
  Dialysis 0.6% 3.2% 0.002 1.0% 4.1% 0.224 0% 5.0% 0.170
  Liver disease 1.7% 4.2% 0.061 8.3% 6.1% 0.634 5.4% 5.0% 0.948
  Malignancy 1.9% 2.1% 0.869 5.2% 4.1% 0.765 8.1% 0% 0.191
BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; FVII, recombinant factor VIIa; MI, myocardial infarction; TBI, traumatic brain 
injury. 
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excluded from further analysis. An additional 322 observa-
tions had no data with respect to rFVIIa administration. The 
final prematched cohort consisted of 3366 individuals not 
receiving rFVIIa and 95 admissions with rFVIIa administra-
tion (figure 1).
Individuals receiving rFVIIa were more likely to be older, 
female, smokers, on warfarin, and have more comorbidities than 
those not receiving rFVIIa (prematching, table 1). Core body 
temperature on arrival in the trauma bay was significantly lower 
in treated patients relative to prematched controls, but there was 
no significant difference for heart rate, systolic blood pressure, 
or GCS score. A greater percentage of patients arriving within 
3 hours of their trauma did not receive rFVIIa, the majority 
presenting 15 minutes to 1 hour post-trauma. Nearly a quarter of 
rFVIIa recipients presented to the emergency department more 
than 6 hours after injury.
ISS and AIS scores were higher for recipients of rFVIIa. 
INR at admission was slightly elevated among those receiving 
rFVIIa (non-significant), and hematocrit was significantly lower 
than controls (38% vs. 33%, P<0.001). Patients receiving 
rFVIIa were more likely to have an intracranial pressure (ICP) 
monitor placed (39.5% vs. 56.8%, P value 0.001) or a craniec-
tomy performed during their hospitalization (22.8% vs. 44.2%, 
P<0.001). Among those with ICP monitoring, the treatment 
group also yielded greater opening pressures relative to controls 
(6 mm Hg vs. 11 mm Hg, P value 0.001). Presence of inhos-
pital attending physician was significantly lower among those 
receiving rFVIIa.
Prematching outcomes
Prior to matching, treatment with rFVIIa was associated with 
a significantly higher likelihood of inhospital mortality (OR 
3.3, CI 2.15 to 4.93; table 3). Although rFVIIa correlated 
with higher rates of abscess, there was no significant increase 
in the overall risk of complication. DVT was confirmed 
in 121 control and 2 rFVIIa patients (P value 0.445). No 
pulmonary embolisms were reported. The mean change in 
GCS score from admission to discharge showed less improve-
ment among rFVIIa recipients (1.8 vs. 5.5, P<0.001), but 
this difference disappeared when GCS change in score from 
24 hours postadmission until discharge was considered 
(table 4). Discharge disposition and mean hospital length 
of stay (LOS) were comparable between groups, whereas 
ICU LOS was significantly longer for those receiving rFVIIa 
(table 4).
Postmatching outcomes, polytrauma patients with TbI
Matching resulted in the identification of 96 controls and 
49 treatment patients, and was balanced across all variables. 
Table 2 Arrival vitals, injury pattern, and key early (<24 hours) laboratory values
Prematching Postmatching, all comers Postmatching, primary TbI
−FVII
(n=3366)
+FVII
(n=95) P value
−FVII
(n=96)
+FVII
(n=49) P value
−FVII
(n=37)
+FVII
(n=20) P value
Penetrating 5.2% 10.6% 0.020 0% 0% 1.000 0% 0% 1.000
Arrival temperature 36 (1.2) 36 (1.4) <0.001 36 (1.1) 36 (1.2) 0.878 36 (1.2) 36 (0.6) 0.910
Arrival HR 97 (26) 96 (27) 0.747 98 (25) 97 (28) 0.821 88 (23) 88 (27) 0.968
Arrival SBP 136 (34) 130 (38) 0.099 138 (36) 138 (35) 0.985 141 (31) 149 (30) 0.344
GCS
On arrival 6.5 (3.8) 6.6 (3.7) 0.832 5.7 (3.1) 7.1 (3.8) 0.020 7.8 (4.0) 7.9 (3.6) 0.991
  At 24 hours 8.8 (4.0) 7.5 (3.6) 0.003 7.8 (3.5) 7.8 (3.6) 0.942 10.3 (3.8) 9.3 (7.3) 0.375
Time to arrival 0.058 0.914 0.021
  <15 minutes 3.4 1.2 2.3 2.4 0.0 0.0
  15 minutes to 1 hour 44.4 39.5 31.0 40.5 51.9 17.6
  >1 hour to 3 hours 29.1 22.2 37.9 16.7 18.5 23.5
  >3 hours to 6 hours 10.6 14.8 12.6 16.7 14.8 23.5
  >6 hours 12.6 22.2 16.1 23.8 14.8 35.3
ISS 27 (13) 32 (13) <0.001 31 (14) 31 (12) 0.921 20 (9) 23 (6) 0.222
  Head AIS 4.1 (0.9) 4.5 (0.6) <0.001 4.4 (0.7) 4.5 (0.6) 0.290 4.2 (0.8) 4.6 (0.6) 0.152
  Chest AIS 1.3 (1.6) 1.8 (1.8) 0.017 1.5 (1.8) 1.7 (1.8) 0.483 0.2 (0.5) 0.1 (0.4) 0.645
  Abdomen AIS 0.6 (1.2) 1.1 (1.5) <0.001 0.9 (1.3) 0.8 (1.3) 0.856 0.2 (0.5) 0.1 (0.3) 0.616
  Spine AIS 0.4 (1.0) 0.7 (1.3) 0.042 0.8 (1.3) 0.9 (1.4) 0.755 0.2 (0.6) 0 (0) 0.197
  Lower extremity AIS 0.8 (1.2) 1.2 (1.5) 0.012 1.2 (1.5) 0.8 (1.2) 0.103 0.2 (0.5) 0.1 (0.2) 0.138
  Upper extremity AIS 0.6 (1.0) 0.8 (1.1) 0.056 0.7 (1.0) 0.9 (1.1) 0.303 0.4 (0.6) 0.2 (0.6) 0.388
INR within 24 hours 1.3 (3.3) 1.7 (0.9) 0.229 1.3 (0.5) 1.5 (0.8) 0.030 1.4 (1.0) 1.7 (1.2) 0.298
Hct within 24 hours 38 (6.7) 33 (8.6) <0.001 33 (8) 34 (8) 0.579 34 (5) 34 (5) 0.722
Decompressive craniectomy 22.8% 44.2% <0.001 36.5% 44.9% 0.325 24.3% 60.0% 0.008
ICP monitor 39.5% 56.8% 0.001 53.1% 63.3% 0.244 46.0% 70.0% 0.082
Initial ICP (mm Hg) 6 (11) 11 (17) <0.001 16 (11) 13 (9) 0.203 15 (9) 12 (9) 0.379
Attending inhouse 80.4% 71.6% 0.034 77.1% 80.0% 0.730 100% 95.0% 0.661
 AIS, Abbreviated Injury Score; FVII, recombinant factor VIIa; GCS, Glasgow Coma Scale; Hct, hematocrit; HR, heart rate; ICP, intracranial pressure; INR, international normalized 
ratio; ISS, Injury Severity Score; SBP, systolic blood pressure; TBI, traumatic brain injury. 
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The average age was 52 and 50 years, respectively, and warfarin 
use in each arm was 9.4% and 14.3% (table 1).
Blunt trauma accounted for 100% of admissions, and 
initial physiology for both groups was comparable (table 2). 
The average GCS score in the trauma bay was lower for those 
not receiving rFVIIa; however, the mean GCS score at 24 hours 
for both groups was 7.8 (P value 0.942). ISS as well as indi-
vidual AIS scores were similar between groups. The average head 
AIS score indicated the presence of a critical head injury (4.4 
no rFVIIa vs. 4.5 rFVIIa), whereas the mean AIS scores for other 
regions reflected minor to moderate injury. INR at admission 
was slightly elevated for both groups (1.3 vs. 1.5) and hematocrit 
indicative of mild anemia was 35% and 34%, respectively. ICP 
monitoring was common in both arms (53.1% vs. 63.3%), and 
no difference in mean opening pressures or rate of decompres-
sive craniectomy was noted (table 2).
After matching, overall mortality and morbidity did not differ 
between treatment groups (table 3). There were 22 deaths 
(22.9%) in the control arm and 15 (30.6%) in the treatment arm 
(P value 0.315). Complication rates were comparable between 
groups. The average GCS score at discharge was 12.1 for matched 
controls and 11.6 for matched patients receiving rFVIIa. The net 
change in GCS score from admission to discharge was lower in 
the treatment group, but again this difference disappeared when 
GCS score at 24 hours was used as a baseline (table 4). The rate 
of discharge to home or rehabilitation facility was comparable 
(71.2% vs. 79.4%). The mean hospital and ICU LOS did not 
differ significantly between groups (table 4).
Figure 1 Study population flow diagram. rFVIIa, recombinant factor VIIa; TBI, traumatic brain injury.
Table 3 Morbidity and mortality outcomes with administration of recombinant FVIIa
Prematching Postmatching, all comers Postmatching, primary TbI
−FVII (%) +FVII (%) or
P value or 
95% CI −FVII (%) +FVII (%) or
P value or 
95% CI −FVII (%) +FVII (%) or
P value or 
95% CI
Mortality 18.9 43.2 3.3* 2.15 to 4.93 22.9 30.6 1.5 0.69 to 3.21 21.6 20.0 0.9 0.24 to 3.48
  +Craniectomy 23.1 40.5 2.3* 1.20 to 4.30 28.6 27.3 0.9 0.28 to 3.08 22.2 16.7 0.7 0.08 to 6.22
  −Craniectomy 17.7 45.3 3.9* 2.22 to 6.68 19.7 33.3 2.0 0.74 to 5.66 21.4 25.0 1.2 0.19 to 7.68
Morbidity 23.6 19.0 0.8 0.45 to 1.27 33.3 22.5 0.6 0.26 to 1.28 17.1 21.1 1.3 0.31 to 5.28
  VAP 12.5 9.5 0.7 0.37 to 1.47 19.8 10.2 0.5 0.16 to 1.32 2.9 0 − − 
  ARDS 4.6 3.2 0.7 0.21 to 2.19 2.1 6.1 3.1 0.50 to 18.99 0 0 − − 
  DVT 3.6 2.1 0.6 0.14 to 2.37 6.3 2.0 0.3 0.04 to 2.67 5.7 0 − − 
  Meningitis 0.8 1.1 1.3 0.17 to 9.42 4.2 2.0 0.5 0.05 to 4.41 0 0 − − 
  Abscess 0.3 2.1 8.0* 1.71 to 37.64 0 0 − − 0 0 − − 
  CRBSI 2.6 1.1 0.4 0.06 to 2.94 6.3 0 − − 0 0 − − 
*P<0.05.
ARDS, acute respiratory distress syndrome; CRBSI, catheter-related blood stream infection; DVT, deep vein thrombosis; FVII, recombinant factor VIIa; TBI, traumatic brain 
injury; VAP, ventilator-associated pneumonia. 
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Postmatching outcomes, patients with primary TbI
Matching with selection for patients who were predominantly 
head-injured resulted in 37 control and 20 treated patients. 
Postmatch analysis revealed no significant differences in key 
demographic variables, including tobacco use and comorbidi-
ties (table 1). Warfarin use was 13.5% in the no-rFVIIa arm and 
25.0% in the rFVIIa group (P value 0.277).
All individuals suffered blunt injuries. Vital signs on arrival 
were not significantly different between groups (table 2). Time 
to arrival was significantly longer among patients receiving 
rFVIIa, with over one-third presenting more than 6 hours after 
injury (table 2). There was no significant difference in ISS and 
body region AIS scores. The mean AIS score for all body regions 
except the head was less than 1, reflecting the large number of 
isolated head injury within this population. The average INR 
within 24 hours of arrival was slightly higher for those receiving 
rFVIIa than for controls (1.4 vs. 1.7), but this difference was 
not significant. Initiation of ICP monitoring was more frequent 
in rFVIIa patients, but this trend was not significant. Decom-
pressive craniectomy was more common in patients receiving 
rFVIIa. Hematocrit and presence of inhouse attending were also 
comparable.
Mortality was 21.6% among controls and 20.0% for those 
treated with rFVIIa (P value 0.886; table 4). Odds of death did 
not differ with rFVIIa use in patients with primary TBI regard-
less of whether they underwent surgical decompression. Eight 
complications were reported in the control group as compared 
with four in the rFVIIa group (P value 0.292). Two patients 
not receiving rFVIIa developed DVT; there were no reported 
cases of DVT in the treatment arm. The mean GCS score at 
discharge was similar between groups (12.8 vs. 12.1), as was the 
percentage of patients discharging to home or a rehabilitation 
facility (82.8% vs. 81.3%). The average improvement in GCS 
score from admission to discharge and from 24 hours postadmis-
sion to discharge did not differ with treatment (table 4). Hospital 
and ICU LOS were also comparable.
DIsCussIon
rFVIIa is approved by the Food and Drug Administration for 
use in hemophiliacs with inhibitors, uncontrolled bleeding, or 
in those undergoing high-risk surgical procedures. The advan-
tages of rFVIIa over blood products and human derived factors 
include its small infusion volume, room temperature storage, 
rapid correction of coagulation parameters, and safety profile 
(eg, absence of transfusion reaction and bloodborne pathogens). 
These characteristics have led to extensive off-label use of rFVIIa 
as an adjunct in the management of coagulopathy in a wide and 
varied number of subpopulations, including patients with coag-
ulopathic trauma. With its ability to rapidly normalize INR, 
while avoiding volume overload, rFVIIa is especially attractive 
as a reversal agent for volume-sensitive patients with TBI or 
hemorrhage.
In this study the propensity score-matched analysis of a large 
prospectively gathered TBI database offers a statistically thor-
ough and robust assessment of the effect of rFVIIa administra-
tion in the head-injured patient. There was no survival benefit 
associated with rFVIIa, a finding consistent with previous retro-
spective and prospective studies.9 13 17-22 Additionally, rFVIIa 
administration was associated with significantly less improve-
ment in GCS score from admission to discharge, and rFVIIa 
did not impact discharge disposition despite comparable ISS 
scores and inhospital complication rates. Although there was 
no specific measure of patient functional status at discharge, 
we interpret these two outcomes as indicating worsened or, at 
best, unchanged neurologic recovery relative to controls. Any 
Table 4 Mean GCS, change (∆) in GCS, hospital and ICU LOS, and disposition outcomes with administration of recombinant FVIIa
Prematching Postmatching, all comers Postmatching, primary TbI
gCs P value gCs P value gCs P value
Mean GCS at discharge <0.001 0.700 0.874
  −FVII 13.3 (2.5) 12.1 (2.9) 12.8 (2.6)
  +FVII 11.9 (3.3) 11.6 (3.5) 12.1 (3.4)
∆GCS admit to discharge <0.001 0.001 0.400
  −FVII 5.5 (4.8) 5.5 (5.3) 4.0 (4.5)
  +FVII 1.8 (5.2) 2.4 (5.6) 2.8 (4.8)
∆GCS at 24 hours to discharge 0.454 0.461 0.510
  −FVII 3.6 (3.6) 3.8 (3.7) 1.5 (3.3)
  +FVII 3.1 (3.8) 3.1 (4.1) 1.6 (3.2)
Days (sD) P value Days (sD) P value Days (sD) P value
Hospital LOS 0.921 0.397 0.940
  −FVII 17.1 (20.9) 21.3 (24.0) 12.4 (10.9)
  +FVII 20.4 (31.5) 17.8 (16.3) 13.6 (14.6)
ICU LOS 0.125 0.787 0.401
  −FVII 10.1 (11.2) 13.3 (14.6) 7.6 (8.1)
  +FVII 13.5 (18.5) 12.3 (12.3) 10.3 (12.4)
% P value % P value % P value
Discharge to home/rehab 0.200 0.370 0.899
  −FVII 81.0 71.2 82.8
  +FVII 74.1 79.4 81.3
FVII, recombinant factor VIIa; GCS, Glasgow Coma Scale; ICU, intensive care unit; LOS, length of stay; TBI, traumatic brain injury.
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deleterious effect that rFVIIa may have on neurologic recovery 
appears to occur early, as the matched groups had comparable 
mean GCS scores at 24 hours after admission. To our knowledge 
there has been no formal evaluation of functional status after 
rFVIIa administration in the setting of trauma reported in the 
literature, and this study represents the first attempt to correlate 
rFVIIa use in TBI with, although crude, neurologic outcomes. 
When the subpopulation of patients with primary head trauma 
was considered, the negative effect of rFVIIa on discharge GCS 
score disappeared. Due to the low number of observations in 
the isolated TBI population, however, it is difficult to draw any 
definitive conclusions from this subgroup analysis.
The clinical benefit of rFVIIa with regard to correction 
of coagulopathy has been well documented in prior studies, 
but improvements in mortality and morbidity have remained 
conspicuously absent.7 8 10 13 18 19 21-25 This discrepancy, along 
with the negative impact on GCS outcomes reported in this 
study, suggests that the beneficial procoagulant effects of 
rFVIIa may be opposed by a deleterious process acting inde-
pendently from the coagulation cascade. There is a growing 
body of literature demonstrating the proinflammatory effects 
of rFVIIa.26-28 Upregulation of proinflammatory factors may 
contribute to the post-traumatic inflammatory response and 
associated complications seen during subsequent hospital-
ization. Thus any clinical benefit of rFVIIa is likely more 
dependent on the degree of hemorrhage and coagulopathy, 
than on injury mechanism or severity. In the patient with 
exsanguinating trauma, for example, the hemostatic benefit 
of rFVIIa may outweigh the negative effects of augmenting 
an already robust inflammatory response. Selecting for a 
population that would most benefit from these hemostatic 
effects likely contributed to the results reported by Rizoli 
and colleagues.20 Inclusion criteria for this study required 
the patient to have already received eight units of RBC prior 
to randomization. rFVIIa administration was associated 
with decreased blood product transfusion rates and a lower 
frequency of inhospital complications, despite no signifi-
cant improvement in mortality. Although the lower inci-
dence of MODS and ARDS among rFVIIa recipients appears 
to contradict the proinflammatory effects of this product 
described above, the reduction in exposure to immunogenic 
blood products relative to controls may have had an overall 
net positive effect.
Limited clinical trials of rFVIIa in the setting of ICH have 
shown mixed results. A randomized, placebo-controlled clin-
ical trial evaluating rFVIIa use in patients not on oral anti-
coagulant therapy (OAT), with spontaneous ICH, reported 
a dose effect of rFVIIa corresponding to slowed intracra-
nial lesion expansion.10 This positive hemostatic effect, 
however, did not translate into an improvement in survival 
or decreased complication rates. A similar study performed 
in a population of traumatic ICH with known lesion ≥2 mL 
on head CT also found rFVIIa to have no effect on mortality 
or morbidity and non-significant trend toward slowed lesion 
expansion relative to placebo.29 Finally, a non-randomized, 
prospective study of low-dose rFVIIa administration in 
patients with coagulopathic (INR >1.2) TBI not on OAT 
reported rapid reversal of coagulopathy and reduction in the 
rate of ICH progression, but no survival benefit.22 Overall, 
the number and quality of studies evaluating rFVIIa use in 
TBI are so few and limited that a Cochrane Review on the 
topic was unable to draw any meaningful conclusions from 
the existing prospective data.7 So it may be that in patients 
with isolated head injuries, the ability of rFVIIa to reduce 
ICH expansion may not be substantial enough to mitigate its 
proinflammatory effects.
This study made use of retrospective data collected from 11 
academic institutions with level 1 trauma designations. Limitations 
as to the applicability of these results must consider the retrospec-
tive nature of the analysis, as well as the generalizability of the 
care provided at these hospitals to other sites across the country. 
There was no standardized dose or protocol used for rFVIIa 
administration, and the indication for its use and timing of admin-
istration were not collected. Likewise, there was no standardized 
treatment protocol employed across centers for TBI management, 
which may obscure any clinical benefit from rFVIIa. Participating 
sites were large academic institutions, each likely to have more 
resources, and to provide a level of care greater than the average 
community hospital. rFVIIa is an expensive adjunct and might not 
be available at lower level or undesignated hospitals. The analysis 
was unable to control for antiplatelet use. Although therapeutic 
doses of rFVIIa may be associated with improved platelet func-
tion, its use in trauma is directed by the depletion of endogenous 
FVII that results from OAT use or trauma-associated coagulop-
athy.30 Since rFVIIa administration would likely not be influenced 
by antiplatelet use, this missing variable is likely evenly distributed 
between matched groups in this analysis. Additionally, pre-rFVIIa 
and post-rFVIIa coagulation lab values were not collected. As 
such, the ability of rFVIIa to normalize INR, PTT, bleed time, 
or various TEG parameters cannot be assessed. Although it is 
possible that rFVIIa resulted in improved survival of a subset of 
more severely injured patients with TBI compared with the control 
group and thus resulted in a lower GCS score at discharge for 
the treatment group, the groups were well matched with regard 
to injury pattern, head CT severity, and physiology on arrival. 
Finally, the impact of rFVIIa on functional outcome was assessed 
crudely using discharge disposition and GCS score at discharge. 
There was no formal evaluation of patient function (eg, activities 
of daily living, Glasgow outcome score or functional scores), and 
the reported statistically significant difference in discharge GCS 
score may not be clinically significant.
ConCLusIon
Consistent with results from prospective and retrospective 
studies, this study found no clinical benefit to support routine 
use of rFVIIa in a patient with trauma. rFVIIa administration was 
associated with decreased GCS levels at discharge, suggesting a 
deleterious effect in this vulnerable population. Use of rFVIIa 
should be abandoned in the trauma.
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